MA-ECHOSENS
21.6.2022 14:58:10 CEST | Business Wire | Press release
Echosens , a high-technology company offering the FibroScan® portfolio of solutions, is pleased to announce its solutions will be included in 22 oral presentations and 157 posters that will evaluate utilization of the non-invasive FibroScan® tool across a variety of liver disease etiologies and practice settings at EASL International Liver Congress™ 2022, June 22-26, 2022, London, United Kingdom. Echosens leaders will present the symposium “FibroScan® Solutions Bringing New Guidelines to Life,” 11 a.m.-12:30 p.m., Meeting Room N19, ExCel London Center, on June 23. Additionally, Echosens will offer “How to Improve Early Screening and Management of Chronic Liver Disease Outside Hospital Setting?” -- two demonstrations of FibroScan® GO, 3 p.m.-4 p.m. or 5:30 p.m.-6:30 p.m. on June 23 in Meeting Room N19, ExCel London.
“This very important meeting furthers the worldwide understanding of liver research, enhances the clinical practice of liver disorders and educates those interested in hepatology,” says Dominique Legros, Group CEO, Echosens. “FibroScan® , the non-invasive solution for comprehensive management of liver health, is recognized worldwide, validated by over 3,500 peer reviewed publications and 160 international guidelines and considered the most widely studied tool for point of care liver assessment.”
Echosens will be available at booth N°46 to discuss and demonstrate early detection with new FibroScan GO, diagnosing and monitoring with FibroScan Mini+ 430 and FibroScan Compact 530, advanced diagnosis and risk stratification with FibroScan Expert 630 live patient demonstration, and digital demonstrations of myFibroScan and Scores by Echosens.
Jon Gingrich, CEO, Echosens North America, adds, “We are thrilled by the global validation of FibroScan and broad consensus of the need for screening and early intervention to prevent advanced liver disease. FibroScan can more cost-effectively identify individuals who are asymptomatic and undiagnosed for liver damage, as well as provide metrics for monitoring changes in liver fat due to lifestyle modification.”
About Echosens
Pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan® , the non-invasive solution for comprehensive management of liver health. FibroScan® is recognized worldwide and validated by over 3,500 peer reviewed publications and 160 international guidelines. Echosens has made FibroScan® available in over 100+ countries enabling millions of liver examinations worldwide. https://www.echosens.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005114/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SIAL Paris 2026: the Event That Sheds Light on and Accelerates the Global Agri-food Industry21.7.2026 12:10:00 CEST | Press release
With just a few months to go until SIAL Paris 2026 (17–21 October, Paris Nord Villepinte), the trade fair has unveiled the findings of its new SIAL Insights 2026 report, an international analysis identifying ten major trends set to bring about lasting change to food markets and consumer behavior. Compiled using exclusive data from Kantar Food 360™, Circana and ProtéinesXTC, the report highlights a more personalised, functional and experiential approach to food, whilst revealing the new trade-offs consumers are making in the face of economic, health and environmental challenges. The 10 key insights into food in 2026 1. Healthy eating: fuel for a high-performing body Consumers are seeking measurable benefits: protein, fiber, energy, immunity or digestive health. 2. The ‘gut brain’: food for mental wellbeing Sleep, stress management, hormonal balance and cognitive performance now influence dietary choices. 3. Pleasure as a conscious experience Premium taste experiences, bold flavors and c
Sagepath Reply Recognized in the 2026 Gartner® Market Guide for Strategic Website Agencies21.7.2026 10:00:00 CEST | Press release
Sagepath Reply, a digital experience agency part of the Reply Group, has been included in the 2026 Gartner Market Guide for Strategic Website Agencies. This marks the third time Sagepath Reply has been named in the Market Guide, following its previous inclusions in 2023 and 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260721481392/en/ Sagepath Reply, a digital experience agency part of the Reply Group, has been included in the 2026 Gartner Market Guide for Strategic Website Agencies. Gartner, a company delivering actionable, objective insight to executives and their teams, defines strategic website agencies as “service providers dedicated to developing website strategies that deliver relevant digital experiences to external audiences. These agencies bundle their strategic marketing services with an array of complementary offerings to support their clients’ needs around website design, development, search value and co
ClickHouse Announced as Principal Partner & Front of Shirt Sponsor of Fulham Football Club21.7.2026 10:00:00 CEST | Press release
Fulham Football Club is proud to announce ClickHouse, a global technology company specialising in real-time analytics, data infrastructure and AI applications, as its newest Principal Partner and Front of Shirt Sponsor of the Men’s First Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260721902779/en/ ClickHouse announced as Principal Partner and Front of Shirt Sponsor of Fulham Football Club This multi-year partnership will see ClickHouse take pride of place on the front of the Men’s First Team home, away and third kits. ClickHouse will also feature across Craven Cottage, the Club’s digital channels, matchday assets and a range of supporter-facing experiences throughout the partnership. The Fulham FC home kit will be released on Thursday 23rd July 2026, keep an eye on the Club’s Instagram for updates. Our collaboration reflects Fulham’s continued focus on innovation, performance and delivering engaging experiences for
CapVest Completes Acquisition of TSG21.7.2026 09:00:00 CEST | Press release
TSG to accelerate its growth as a leading multi-energy infrastructure services provider across Europe; management and HLD reinvesting alongside CapVest as significant minority shareholders CapVest Partners LLP (“CapVest”), a leading New York and London based investment firm, today announces that it has completed its acquisition of a majority stake in TSG Solutions (“TSG”), a European leader in technical services for critical energy infrastructure, following receipt of all necessary approvals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260721628079/en/ TSG Headquartered in Paris, France, TSG operates across 30 countries with over 7,000 employees and annual revenues of more than €1.4 billion. The company designs, builds and maintains critical energy infrastructure across Power (HV, MV & LV electrical), Charge, Solar, Battery Energy Storage Systems (BESS), Biofuels and Gas & Biogas. TSG’s multi-energy capabilities, deep tec
European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union21.7.2026 09:00:00 CEST | Press release
Approval expands the approved indication for Crysvita to include infants from 1 month to 1 year of age, enabling earlier intervention in a rare, progressive disease that can impact skeletal development from infancy.Approval applies across the European Union and European Economic Area, expanding access to treatment for the youngest patients living with XLH. Kyowa Kirin EMEA, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151), today announced that the European Commission (EC) has approved an expansion of the indication for Crysvita® (burosumab) for the treatment of X-linked hypophosphataemia (XLH), to include infants from 1 month to 1 year of age across the European Union and European Economic Area. The approval represents an important step forward for infants living with XLH, a rare, progressive genetic disease that can affect skeletal development from an early age. Earlier diagnosis and treatment are considered important in XLH given the potential impact of the disease on sk
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom